Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118347 | 0.81 | TSHR (0.37) | TSHRKMT2AL3MBTL1KDM4E | |
| SCHEMBL27412041 | 0.78 | CA1 (0.48) | TSHRALDH1A1CYP1A2MEN1CYP3A4 | |
| SCHEMBL27411561 | 0.78 | CA1 (0.48) | TSHRALDH1A1CYP1A2MEN1CYP3A4 | |
| SCHEMBL391840 | 0.77 | TSHR (0.59) | TSHRL3MBTL1KDM4EGABRA1GABRB2 | |
| SCHEMBL26029124 | 0.76 | ALDH1A1 (0.39) | TSHRALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL22969912 | 0.76 | ADRB2 (0.43) | TSHRALDH1A1CYP1A2CYP3A4L3MBTL1 | |
| SCHEMBL820441 | 0.73 | TSHR (0.41) | TSHRGABRA1GABRB2SMN1; SMN2 | |
| SCHEMBL28762361 | 0.73 | CD44 (0.38) | TSHRALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4769774 | 0.72 | GABRA1 (0.33) | TSHRCYP1A2CYP3A4LMNAHPGD | |
| SCHEMBL233609 | 0.71 | GABRA1 (0.50) | TSHRALDH1A1MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802895-B2 | Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same | CLEVELAND STATE UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2629767-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | Cleveland State University (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054417-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | RB1, BCR, NRAS | TSHR 493/4885ALDH1A1 639/4885MAPT 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.